Hepatitis C Virus Recurrence Occurs Earlier in Patients Receiving Donation After Circulatory Death Liver Transplant Grafts Compared With Those Receiving Donation After Brainstem Death Grafts.

•This article reports the experience of the UK's largest liver transplant centre of patients receiving DCD liver grafts and compares their outcomes to a matched cohort of individuals receiving DBD liver grafts for hepatitis C-related liver disease.•HCV recurrence was more rapid in DCD recipients; other risk factors were CMV infection and steroid use post-transplantation.•Five-year patient and graft survival and rates of biliary complications were equal in both groups.•On average DCD donor age was 10 years older than in other published cohorts, supporting the uses of extended-criteria DCD grafts.•In an era of highly effective DAA therapy, rapid HCV recrudescence in grafts from DCD donors should not compromise long-term morbidity or mortality, but clinicians should be aware that early post-transplant antiviral therapy is indicated to prevent graft injury.